| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Protarga, Inc. |
| 2200 Renaissance Boulevard, Suite 450, King of Prussia, PA 19406 * (610) 592-4000 |
| Business Description | The company is a clinical stage pharmaceutical company that is developing new, patentable drugs for the treatment of cancer, central nervous system disorders and infectious diseases. All our product candidates employ our proprietary Targaceutical platform technology, which entails chemically linking a specific fatty acid molecule to a pharmaceutical agent. |
|
Filing Information Not yet | |||
| To Trade As | PRTG (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 12/11/2001 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $75,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| UBS Warburg LLC | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1998 | 12/31/1999 | 12/31/2000 | 9/30/2000 | 9/30/2001 | ||
| Revenues | - | - | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Income from Oper. | - | - | -3.861 | -5.077 | -9.059 | -5.446 | -13.942 |
| Net Income | - | - | -3.781 | -5.006 | -8.797 | -5.344 | -13.632 |
| E.P.S | - | - | -12.440 | -16.170 | -24.220 | -14.760 | -31.930 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -7.37 | -5.16 | -10.81 | ||||
| Cash Flow - Inv. | -0.32 | -0.28 | -0.41 | ||||
| Cash Flow - Fin. | 18.43 | 15.40 | 4.41 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/2001 | Financial Ratios | ||||
| Total Assets | 4.99 | Current Assets | 4.27 | Current Ratio | 1.55 |
| Total Liab. | 2.80 | Current Liab. | 2.76 | Debt Ratio | 56.08% |
| Total Equity | 2.19 | Working Cap. | 1.52 | Debt to Equity Ratio | 1.28 |
| Cash | 4.22 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for further development of Taxoprexin , research and development of additional product candidates, business development, including product licensing and potential acquisitions, and general corporate purposes |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Bingham, Dana & Gould |
| Bank's Law Firm | Dewey Ballantine |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Koerner Capital Corporation | 14.30 | |
| Shashoua Voting Trust | 11.10 | |
| EquityFourLife (Bahamas) Ltd. | 7.30 | |
| Note: represents ownership of 5% or more prior to the offering. | ||